A phase Ib, first-in-human, dose escalation and expansion study of XMT-1522, a novel antibody-drug conjugate (ADC) directed against HER2, in patients with advanced breast cancer and other advanced tumors expressing HER2.

Howard A. Burris,Minal Barve,Erika Paige Hamilton,Aditya Bardia,Hatem Soliman,Donna Jarlenski,Rebecca Mosher,Donald Alan Bergstrom

A phase Ib, first-in-human, dose escalation and expansion study of XMT-1522, a novel antibody-drug conjugate (ADC) directed against HER2, in patients with advanced breast cancer and other advanced tumors expressing HER2.

2017

Howard A. Burris
Minal Barve
Erika Paige Hamilton
Aditya Bardia
Hatem Soliman
Donna Jarlenski
Rebecca Mosher
Donald Alan Bergstrom

TPS2606Background: XMT-1522 is an ADC consisting of a novel human IgG1 anti-HER2 monoclonal antibody conjugated to an auristatin-based cytotoxic payload (AF-HPA). An average of 12 AF-HPA molecules ...

Keywords:

Breast cancer
Cancer research
Pathology
Medicine
Antibody-drug conjugate
in patient
first in human
Cytotoxic T cell
Cancer
dose escalation
Monoclonal antibody
advanced breast

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations